Over 70% of cancer metastasis from prostate cancer develops bone metastases that are not sensitive to hormonal therapy, radiation therapy, or chemotherapy. The epithelial-to-mesenchymal transition (EMT) genetic program is implicated as a significant contributor to prostate cancer progression. | Berberine inhibits the metastatic ability of prostate cancer cells by suppressing epithelial to mesenchymal transition (EMT) associated genes with predictive and prognostic relevance
